Paramount Skydance Corporation Announces Extension of Expiration Dates of Previously Announced Exchange Offers and Tender Offers

LOS ANGELES and NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Paramount Skydance Corporation (NASDAQ: PSKY) ("Paramount") today announced the extension of the Expiration Dates in connection with the previously announced (i) offers to purchase (the "Tender Offers" and each, a "Tender Offer") for cash, upon the terms and subject to the conditions set forth in the related offer to purchase (the "Offer to Purchase"), any and all of the identified notes in each series of the Existing Tender Offer Notes (defined by reference to the table set forth below) issued by Discovery Global Holdings, Inc. (formerly WarnerMedia Holdings, Inc.) (the "DGH Issuer") and Discovery Communications, LLC (the "DCL Issuer" and together with the DGH Issuer, each a "WBD Issuer" and collectively the "WBD Issuers"), as applicable, and (ii) offers to exchange (the "Exchange Offers" and each, an "Exchange Offer" and, together with the Tender Offers, the "Offers" and each, an "Offer"), upon the terms and subject to the conditions set forth in the related exchange offer memorandum (the "Offering Memorandum"), any and all of the identified notes in each series of the Existing Exchange Offer Notes (defined by reference to the table set forth below) (together with the Existing Tender Offer Notes, the "Offer Notes") issued by the applicable WBD Issuer for notes to be newly issued by Paramount.

The Expiration Dates for the Tender Offers and Exchange Offers (as defined in each of the Offer to Purchase and Offering Memorandum, respectively) have been extended to 5:00 p.m., New York City time, on October 2, 2026, unless further extended. The Settlement Dates for the Tender Offers and Exchange Offers (as defined in each of the Offer to Purchase and Offering Memorandum, respectively) will occur promptly after the Expiration Date and are currently anticipated to occur in the third quarter of 2026. Paramount anticipates extending the Expiration Date for such Tender Offers and Exchange Offers until such time that would result in the Settlement Dates occurring on or promptly following the closing date of the proposed acquisition (the "Acquisition") by Paramount of Warner Bros. Discovery, Inc. ("WBD"). Tenders of the Offer Notes in the Offers may be withdrawn at any time prior to the Expiration Date. The aforementioned extensions further extend the Expiration Dates previously extended by Paramount on June 12, 2026, June 26, 2026, July 13, 2026, July 17, 2026, July 24, 2026, July 31, 2026, August 7, 2026, August 17, 2026, August 24, 2026, August 31, 2026, September 8, 2026, and September 14, 2026.

As of 5:00 p.m., New York City time, on September 18, 2026, approximately 66.87% and 75.12% of the aggregate principal amount of the Existing Tender Offer Notes and Existing Exchange Offer Notes, respectively, have been validly tendered in the applicable Offers. As Paramount previously announced that it anticipates extending the Offers to align with the closing date of the Acquisition, Paramount does not view these figures to be representative of the final results of the applicable Offers.

Information about each series of Offer Notes eligible to participate in the Offers is summarized below.

The Exchange Offers are being made pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations of the Securities and Exchange Commission (the "SEC") promulgated thereunder, and are also not being registered under any state or foreign securities laws. Any securities offered pursuant to the Exchange Offers may not be offered or sold in the United States or to any U.S. persons (as defined below) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Exchange Offers will only be made, and the securities offered pursuant to the Exchange Offers are only being offered and issued, to holders of applicable Existing Exchange Offer Notes who are (a) reasonably believed to be "qualified institutional buyers" as defined in Rule 144A under the Securities Act or (b) not "U.S. persons," as defined in Rule 902 of Regulation S under the Securities Act (such holders, "Eligible Holders"), and only Eligible Holders who have completed and returned the eligibility certification are authorized to receive or review the Offering Memorandum or to participate in the Exchange Offers. The eligibility certification is available electronically at: https://gbsc-usa.com/eligibility/paramount.

General

Each Offer is a separate offer, and each may be individually consummated, amended, extended, terminated, or withdrawn, subject to certain conditions and applicable law, at any time in Paramount's sole discretion, and without also consummating, amending, extending, terminating, or withdrawing any other Offer with respect to any other series of Offer Notes. Paramount may terminate an Offer if any of the conditions of such Offer described in the Offer to Purchase or Offering Memorandum, as applicable, are not satisfied or waived by the applicable Expiration Date, subject to applicable law. In addition, Paramount may waive the conditions to an Offer without extending such Offer in accordance with applicable law.

The Offers are being made solely by Paramount and are not being made by WBD or the WBD Issuers. None of Paramount, WBD, the WBD Issuers, the Dealer Managers, the Exchange Agent (as defined below), the Information Agent (as defined below), the trustees under each of the indentures governing the Offer Notes, the trustee or collateral agent under the indenture that will govern the notes to be issued in the Exchange Offers, or any affiliate of any of them makes any recommendation as to whether any holder of Offer Notes should tender or refrain from tendering all or any portion of the principal amount of such holder's Offer Notes for cash or notes to be issued in the Exchange Offers. No one has been authorized by any of them to make such a recommendation. Holders must make their own decision whether to tender Offer Notes in any Offer and, if so, the amount of Offer Notes to tender.

Only Eligible Holders may receive a copy of the Offering Memorandum and participate in the Exchange Offers. Paramount has engaged Global Bondholder Services Corporation to act as the exchange agent (in such capacity, the "Exchange Agent") and information agent (in such capacity, the "Information Agent") for the Offers. Questions concerning the Offers, or requests for additional copies of the Offer to Purchase or Offering Memorandum or other related documents, may be directed to Corporate Actions by telephone at (855) 654-2014 (U.S. toll-free) or (212) 430-3774 (banks and brokers) or by email at [email protected]. Holders should also consult their broker, dealer, commercial bank, trust company or other institution for assistance concerning the Offers. The Exchange Offer documents and the Tender Offer documents can be accessed at the following link: https://gbsc-usa.com/paramount.

Paramount has engaged BofA Securities and Citigroup as dealer managers (in such capacity, the "Dealer Managers") for the Offers. Holders with questions regarding the Offers should contact BofA Securities, Inc. at +1 (888) 292-0070 (toll-free) or +1 (980) 388-3646 (collect) or [email protected] or Citigroup Global Markets Inc. at +1 (800) 558-3745 (toll-free) or +1 (212) 723-6106 or ny.liabilitymanagement@citi.com. Latham & Watkins LLP is serving as legal counsel to Paramount and Cahill Gordon & Reindel LLP is serving as legal counsel to the Dealer Managers.

This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security, and does not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

About Paramount, a Skydance Corporation

Paramount, a Skydance Corporation is a next-generation global media and entertainment company, comprised of three business segments: Studios, Direct-to-Consumer, and TV Media. PSKY's portfolio unites legendary brands, including Paramount Pictures, Paramount Television, CBS, CBS News, CBS Sports, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount+, Pluto TV, and Skydance Animation, Film, Television, Interactive/Games, and Paramount Sports Entertainment.

PSKY-IR

Cautionary Note Concerning Forward-Looking Statements

This communication contains "forward-looking statements" regarding the Acquisition and the other transactions referred to herein. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Paramount.

PUNE, India, Sept. 21, 2026 /PRNewswire/ -- The Global Pharmaceutical Logistics Market Size was valued at approximately USD 100.0 Billion in 2025 and is projected to expand at a strong 7.7% CAGR from 2026 to 2034, reaching approximately USD 194.0 Billion by 2034.

Global Pharmaceutical Logistics Market

Global Pharmaceutical Logistics Market Report 2025 provides a comprehensive analysis of market trends, size, and forecasts through 2034. The industry is expanding alongside the growth of pharmaceutical manufacturing, international drug distribution, biologics, vaccines, and specialty medicines. Rising demand for cold-chain and temperature-controlled logistics is driving investments in refrigerated transportation, specialized warehousing, cold storage, and real-time temperature monitoring. Meanwhile, IoT-enabled monitoring, GPS tracking, digital shipment visibility, automated warehouse systems, and specialized pharmaceutical transportation are improving supply-chain control, traceability, and product integrity. The increasing role of third-party logistics providers is further supporting integrated pharmaceutical transportation, warehousing, inventory management, and distribution services across global markets.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/108428/

Global Pharmaceutical Logistics Market expands with cold-chain infrastructure and digital supply chain solutions: Maximize Market Research unveils key insights.

Global Pharmaceutical Logistics Market Size & Forecast:

Pharmaceutical Logistics Market Trends & Insights:

- North America remains a significant regional market, supported by established pharmaceutical and biotechnology industries, advanced healthcare infrastructure, and sophisticated distribution networks.

- Asia-Pacific is emerging as an important growth center, driven by expanding pharmaceutical manufacturing, increasing healthcare expenditure, pharmaceutical exports, and developing distribution infrastructure.

- Cold-chain logistics is witnessing strong demand due to the growing distribution of biologics, vaccines, specialty medicines, and other temperature-sensitive pharmaceutical products.

- Digitalization of pharmaceutical logistics is accelerating through IoT-enabled monitoring, GPS tracking, real-time shipment visibility, track-and-trace systems, and digital supply-chain platforms.

- Third-party logistics providers are expanding their role by offering integrated transportation, warehousing, cold-chain, inventory management, order fulfillment, and distribution services.

Cold-Chain Expansion and Pharmaceutical Trade Drive Global Pharmaceutical Logistics Market Growth Opportunities

Global Pharmaceutical Logistics Market is gaining strong strategic momentum as pharmaceutical manufacturing, international drug distribution, biologics, vaccines, and specialty medicines expand across global healthcare supply chains. Rising demand for cold-chain and temperature-controlled logistics is increasing the need for refrigerated transportation, specialized warehousing, cold storage, and real-time temperature monitoring. The growing role of third-party logistics providers is further expanding Pharmaceutical Logistics Market Growth Opportunities through integrated transportation, inventory management, order fulfillment, and distribution services.

Temperature-Sensitive Products, Regulatory Compliance, and Supply-Chain Complexity Restrain Global Pharmaceutical Logistics Market Growth

Pharmaceutical Logistics Market faces operational challenges associated with maintaining product quality, regulatory compliance, and controlled environmental conditions throughout transportation and storage. Temperature-sensitive pharmaceuticals require validated cold-chain infrastructure, specialized handling, continuous monitoring, and reliable distribution networks. Complex cross-border pharmaceutical supply chains and the need for traceability can increase operational requirements, creating challenges for scalable logistics deployment across different regions.

Digital Tracking, IoT Monitoring, and Specialized Logistics Unlock Global Pharmaceutical Logistics Market Opportunities

Pharmaceutical logistics is entering a technology-driven transformation phase as IoT-enabled monitoring, GPS tracking, real-time shipment visibility, track-and-trace systems, and digital supply-chain platforms improve control across pharmaceutical distribution networks. Growing adoption of automated warehouse systems and digitally monitored transportation is strengthening traceability, inventory management, and shipment visibility. At the same time, increasing demand for biologics, vaccines, specialty medicines, and advanced therapies is creating Pharmaceutical Logistics Market Growth Opportunities for specialized logistics providers and integrated cold-chain solutions.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/108428/

Cold-Chain Infrastructure, Digital Tracking, and Specialized Transportation Transform Global Pharmaceutical Logistics Market

Temperature-Controlled Logistics: Increasing volumes of biologics, vaccines, specialty medicines, and other temperature-sensitive pharmaceutical products are driving demand for refrigerated transportation, cold storage, specialized warehousing, and real-time temperature monitoring across global supply chains.

Digital Shipment Visibility: IoT-enabled monitoring, GPS tracking, track-and-trace systems, and digital supply-chain platforms are improving shipment visibility, traceability, inventory control, and monitoring throughout pharmaceutical logistics operations.

Specialized Pharmaceutical Transportation: Secure and compliant transportation solutions are becoming increasingly important for maintaining product quality, safety, and controlled environmental conditions, while third-party logistics providers are expanding integrated transportation, warehousing, inventory management, and distribution capabilities.

Cold-Chain Logistics and Digital Tracking Drive Global Pharmaceutical Logistics Market Segmentation Insights

Global Pharmaceutical Logistics Market by Service, Type, and Application is strategically shaped by the growing demand for transportation, warehousing, distribution, inventory management, and temperature-controlled logistics across pharmaceutical supply chains. Increasing volumes of biologics, vaccines, specialty medicines, and temperature-sensitive products are strengthening demand for cold-chain transportation, specialized warehousing, and real-time monitoring. At the same time, IoT-enabled monitoring, GPS tracking, digital shipment visibility, and track-and-trace systems are improving pharmaceutical logistics efficiency, traceability, and regulatory compliance.

By Service

Transportation

Warehousing

Distribution

Inventory Management

Order Fulfillment

Value-Added Services

By Type

Cold Chain Logistics

Non-Cold Chain Logistics

By Application

Pharmaceutical Manufacturing

Biologics and Specialty Medicines

Vaccines

Clinical Trial Materials

Other Pharmaceutical Products

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/108428/

North America Leads While Asia-Pacific Expands: Key Regional Insights Driving Global Pharmaceutical Logistics Market

North America is a significant region in the Global Pharmaceutical Logistics Market, supported by its established pharmaceutical and biotechnology industries, advanced healthcare infrastructure, sophisticated distribution networks, and developed cold-chain capabilities. Growing demand for biologics, specialty medicines, vaccines, and clinical trial materials is increasing the need for validated cold-chain transportation, specialized warehousing, real-time shipment monitoring, and compliant pharmaceutical distribution. The expanding role of third-party logistics providers and digital supply-chain technologies is further strengthening regional logistics capabilities.

Asia-Pacific is emerging as an important growth center in the Global Pharmaceutical Logistics Market, supported by expanding pharmaceutical manufacturing, rising healthcare expenditure, increasing pharmaceutical exports, and developing distribution infrastructure. China and India are major contributors, while Japan, South Korea, Singapore, and Australia are supporting regional logistics development. Growing demand for biologics, vaccines, specialty pharmaceuticals, temperature-controlled transportation, specialized warehousing, and digitally monitored supply chains is creating significant Pharmaceutical Logistics Market Growth Opportunities across the region.

DHL Supply Chain, UPS Healthcare & FedEx Drive Global Pharmaceutical Logistics Market with Cold-Chain and Digital Logistics Innovations

DHL Supply Chain is strengthening its pharmaceutical logistics capabilities through expanded cold-chain infrastructure, healthcare facilities, dedicated solutions for biologics, vaccines, and advanced therapies, along with digital monitoring and temperature-controlled logistics.

UPS Healthcare is expanding temperature-controlled infrastructure and specialized handling capabilities for pharmaceutical and complex healthcare products, strengthening cold-chain connectivity and reliable distribution across healthcare supply chains.

FedEx is strengthening its life-sciences logistics capabilities for medicines, biologics, medical devices, and clinical trial materials through specialized handling and certified pharmaceutical transportation solutions.

Helping Advance Industry Collaboration, Innovation and the Future of Global Supply Chains

SEOUL, South Korea and TEANECK, N.J., Sept. 21, 2026 /PRNewswire/ -- LX Pantos Americas is proud to announce its Regional Sponsorship and participation in the VMA26 International Trade Symposium, a premier industry event that brings together business leaders, innovators and supply chain professionals to explore the trends, challenges and opportunities shaping the future of global trade and maritime commerce. The event will take place October 13-15 at the Hilton Norfolk The Main in Norfolk, Virginia.

LX Pantos Americas' participation in VMA26 reflects the company's deep commitment to maritime transportation and growing investment in Virginia as a strategic gateway for global trade. The company has strengthened its presence in the Commonwealth through recent Memorandums of Understanding with The Port of Virginia and the Virginia Economic Development Partnership (VEDP), reinforcing a shared focus on trade growth, supply chain innovation and economic development. These relationships position LX Pantos Americas to support customers with enhanced connectivity and logistics solutions while contributing to Virginia's role as a leading hub for international commerce.

As economic ties between the United States and Korea continue to expand, LX Pantos Americas is closely aligned with the opportunities emerging from increased Korean investment across North American manufacturing, infrastructure and transportation networks. The company is actively evaluating opportunities related to the anticipated $150 billion shipbuilding collaboration initiative between the U.S. and Korea and the broader supply chain ecosystem it is expected to support. LX Pantos Americas will host a private executive roundtable during VMA26, bringing together business and supply chain leaders to explore how strategic investment, collaboration and resilient infrastructure can be leveraged to create long-term competitive advantage in a rapidly evolving global marketplace.

LX Pantos Americas CEO David Bang will participate in Late Night Freight on Thursday, October 15, at 11:15 a.m. with host Eric Jehu, VP, Logistics for the VEDP, where he provides primary staff leadership for developing and implementing strategies to promote employment growth within Virginia's logistics industry. The session will bring together leaders from the legal, pharmaceutical and logistics sectors to discuss the policy, infrastructure and investment priorities shaping the future of supply chains. Bang will share LX Pantos Americas' "supply chain forward" perspective, emphasizing the importance of collaboration, strategic investment and policy alignment in building resilient supply chains and supporting sustainable industry growth.

Reflecting its commitment to fostering future industry talent, LX Pantos Americas will sponsor a student's participation in VMA26 and welcome a student guest to its sponsored table at the Maritime Banquet, helping connect emerging professionals with industry leaders while supporting the next generation of maritime, logistics and international trade talent.

"Virginia continues to play an increasingly important role in global trade, making VMA26 an ideal forum to discuss the opportunities created by growing investment and collaboration across the supply chain ecosystem," said David Bang, CEO of LX Pantos Americas. "As economic ties between the United States and Korea deepen, we see significant potential to strengthen maritime transportation, infrastructure and logistics networks. Through our partnerships in Virginia and engagement with industry leaders at VMA26, we look forward to contributing to conversations that help transform investment into long-term economic growth and supply chain resilience."

- About LX Pantos Americas

LX Pantos Americas is the Americas regional organization of LX Pantos, a leadingglobal logistics company. With operations spanning across North and South America, LX Pantos Americas combines global scale and standards with deep regional expertise and local execution excellence. The company delivers optimized, end-to-end logistics solutions tailored to support business growth across a wide range of industries, while actively contributing to the communities it serves. LX Pantos Americas brings customers closer to their end markets faster, through all modes of transportation and contract logistics capabilities, including last mile delivery and installation services offered through InstallX, leveraging deep expertise and advanced technical knowledge. The company's StarLinks service provides reliable and competitive ground transportation solutions across North America powered by its partners and BoxLinks – an innovative joint venture with a major ocean shipping line – enhancing intermodal transport solutions. Driven by a strong dedication to service excellence and client success, LX Pantos Americas helps customers move forward with confidence. Learn more about LX Pantos Americas online and follow it on LinkedIn.

- About LX Pantos

Established in 1977, LX Pantos is a leading global logistics provider headquartered in Korea. It delivers comprehensive logistics solutions across sea, air, rail, and contract logistics through a worldwide network spanning more than 40 countries.

Learn more about LX Pantos online and follow it on LinkedIn.

SOURCE LX Pantos

Share this article

Guarantor Platform Helps Properties Approve Qualified Renters as Concessions Climb and Rents Fall

PHOENIX, Sept. 21, 2026 /PRNewswire/ -- Cosign, a third-party guarantor platform and cosigner alternative designed to expand renter access while protecting property owners, has launched in the Phoenix-Mesa-Chandler MSA as the Valley works through some of the highest apartment vacancy in the country.

According to CoStar, apartment vacancy across Maricopa County and the broader Phoenix-Mesa-Chandler MSA sits at 10.8%, still near the highest level since the Great Recession despite improving from a peak of 12.6%. The metro ranks among the nation's top 10 highest-vacancy markets, alongside fellow Sun Belt builders like Austin, Charlotte and San Antonio. Asking rents fell 1.2% over the past year, and operators are leaning harder on concessions, with 10 or more weeks of free rent now common at newly built communities.

At Zendoor, a Phoenix-based multifamily property management company, the team has adopted Cosign to help streamline apartment approval for renters who can afford the rent but get screened out by rigid legacy criteria.

"At Zendoor, we're seeing that many renters who may not meet traditional screening criteria can still be responsible, qualified residents," said Jessa Mae, the resident support team lead at Zendoor. "Having flexible solutions that give these applicants another path to approval can help property managers reduce unnecessary denials while making it easier to fill homes across the Phoenix market."

Founded by real estate owners and operators, Cosign uses a data-driven underwriting model that evaluates payment behavior and recency rather than relying solely on credit scores. The platform is designed to help owners fill units faster without lowering standards, a case that matters most in markets like Phoenix where every leased unit counts against a deep supply overhang.

"Phoenix is a market where owners can't afford to lose a qualified renter over a technicality," said Zach Schofel, co-founder and CEO of Cosign. "When vacancy is this high, the properties that win are the ones saying yes to renters who can actually pay, and that's exactly what we help them do."

For more information, visit www.rentwithcosign.com and follow on social media @rentwithcosign.

About Cosign

Cosign is a real estate technology company and lease guarantor service that bridges the gap between qualified renters and landlords. Founded by real estate professionals, Cosign's mission is to expand housing access through data-driven underwriting that considers payment behavior, not just credit scores. Active in more than 600,000 units across 3,000+ communities nationwide, Cosign is helping modern operators approve more qualified renters in both tight and oversupplied markets. For more information, visit www.rentwithcosign.com.

SOURCE Cosign

Share this article

New PrSM demonstrates moving target engagement expanding the U.S. Army's mission set

DALLAS, Sept. 21, 2026 /PRNewswire/ -- The U.S. Army has awarded Lockheed Martin (NYSE:LMT) an indefinite delivery, indefinite quantity (IDIQ) contract worth up to $1.2 billion to produce Increment 2 of the Precision Strike Missile (PrSM), further strengthening the nation's Arsenal of Freedom after a second flight test demonstrated the missile's ability to engage moving maritime targets.

THE BIG PICTURE

- Contract: The IDIQ covers initial procurement and future orders of PrSM Increment 2 missiles, follow-on production and continued development. Work will be performed at Lockheed Martin facilities and across the company's U.S. industrial base.

- Test: PrSM Increment 2 completed its first flight test in March and its second flight test in August – obtaining critical data during flight, launching from a HIMARS, deploying protective covers and engaging the target. Technologies developed through Lockheed Martin's Strigo family of solutions have informed aspects of the PrSM Increment 2 guidance package. Additional PrSM Increment 2 flight tests are scheduled for 2027.

- Investment: This award builds on the Department of War's broader investment in PrSM. Lockheed Martin is expanding capacity to quadruple PrSM production while continuing to develop additional PrSM increments.

WHY IT MATTERS

The award moves PrSM Increment 2 from development and flight testing into production, advancing the Army's next-generation long-range precision fires capability. Increment 2 adds a multimode seeker designed to enable the missile to engage moving land and maritime targets, expanding the Army's long-range strike options.

EXPERT PERSPECTIVE

- "This award marks an important step in delivering PrSM Increment 2 to the warfighter," said Dave Griser, vice president, Precision Fires Launchers and Missile, Lockheed Martin. "We're ready to move from flight testing into production and provide the Army with an expanded long-range precision fires capability."

ADDITIONAL CONTEXT

- What's Next: Lockheed Martin will begin production of the initial Increment 2 missiles while continuing flight testing and system maturation. The company is positioned to scale production as the Army moves toward larger Increment 2 procurements.

About Lockheed Martin

Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com. 

SOURCE Lockheed Martin

Share this article

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain

Site will employ more than 600 people in high-wage jobs

$12.5 million in support to build talent pipeline, workforce training center with San Jacinto College

HOUSTON, Sept. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites — and fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020. As part of the company's $50 billion push to reshore medicine production to meet growing demand at home and export American-made medicines to people around the world, the $6.5 billion Houston site will manufacture Foundayo (orforglipron), Lilly's first synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics.

Foundayo is a GLP-1 receptor agonist approved in the U.S. for weight management in adults with obesity, or adults with overweight and a weight-related condition. It is a small molecule rather than a peptide; small molecules are manufactured using more well-established technologies and therefore can be more readily scalable. Foundayo is currently under regulatory review in more than 40 countries, with a full global rollout targeted for 2027. Lilly is also studying Foundayo for other uses, including type 2 diabetes and obstructive sleep apnea, with data expected later this year.

David A. Ricks, Lilly Chair and CEO: "We are thrilled to break ground on our latest 'medicines made in America' site in the great state of Texas. This $6.5B investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly's latest products from Texas to people here at home and around the world."

Building a talent pipeline in Houston

Lilly is providing $12.5 million to support a relationship with San Jacinto College to give Houstonians a pathway into advanced chemical synthesis manufacturing careers, with no prior experience required. This relationship will focus on developing training pathways and expanding the equipment and facility capacity needed to produce technicians, operators, maintenance professionals, and other manufacturing talent, while also leveraging Lilly experts to support curriculum development and instructor readiness and preparation. Separately, Lilly is providing a $2.5 million charitable donation to the San Jacinto College Foundation to support scholarships for eligible students.

Lilly is currently hiring in Houston and expects the new facility to create more than 600 high-wage jobs like engineers, scientists, operations personnel, and lab technicians — along with 4,000 construction jobs as the site is being built and brought online. Visit the Lilly Houston career page for open positions or join Lilly's talent community for future opportunities.

Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations: "When you invest in a place like Houston, you invest in its people first. This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home. The facility itself is being built to the highest standards for safety, quality and responsible stewardship of the environment, and every one of these jobs helps bring innovative medicines to the patients counting on them."

In addition to Foundayo, the Houston site will focus on advanced therapeutics that were not within reach even a few years ago. This will include oligonucleotides, a class of medicines that can work at the genetic level to switch off the production of specific proteins to treat disease closer to its source.

Texas Governor Greg Abbott: "Texas is the global hub for life sciences. This $6.5 billion Lilly investment in Houston is the largest active pharmaceutical ingredient project in Texas history and will create more than 600 high-wage jobs, right here in Texas. Texas will produce these medicines at home so we can deliver life-changing treatments to millions of Americans."

Producing this pipeline of medicines at scale requires manufacturing capacity built to match the pace of innovation. Lilly has announced ten U.S. sites since 2020:

The Houston site will use state-of-the-art technologies, including machine learning, AI, digitally integrated systems and advanced data analytics to drive right-first-time execution. Digital automation will be embedded throughout the site to streamline operations and ensure a reliable supply of safe, high-quality medicines.

Additional quotes for media use

Dr. Brenda Hellyer, Chancellor of San Jacinto College: "Eli Lilly's manufacturing investment in Generation Park is a tremendous opportunity for the Houston region. San Jacinto College is proud to work with Lilly to develop the skilled workforce needed to support the growth of biopharmaceutical manufacturing. Together, we will expand industry-informed education and hands-on training pathways that prepare students and incumbent workers with the technical skills these advanced manufacturing careers require. This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region."

For media use:

About Foundayo™ (orforglipron)

Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day with no planning around food or drink.2 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orfoglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

INDICATION AND SAFETY SUMMARY WITH WARNINGS

Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Warnings — Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Review these questions with your healthcare provider:

How to take

Learn more

Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.

OLIVE TREE PEOPLE'S FIRST OLIVE GROVES SUCCESSFULLY COMPLETE THEIR DEMETER AUDIT — PLACING THE WATERLESS BEAUTY PIONEER AMONG A VERY SMALL GROUP OF BEAUTY COMPANIES WORLDWIDE WITH THEIR OWN BIODYNAMIC AGRICULTURAL RESOURCES AT THE SOURCE OF THEIR BEAUTY.

ANDALUSIA, Spain, Sept. 21, 2026 /PRNewswire/ -- Most beauty companies buy ingredients.

OLIVE TREE PEOPLE grows them.

And very few beauty companies in the world can say what OLIVE TREE PEOPLE can say today:

Our beauty begins on our own land, with our own trees — and our first olive groves have now successfully completed their Demeter audit with outstanding results.

Formal certification is pending completion of the certification process.

This places OLIVE TREE PEOPLE among a remarkably small group in the global beauty industry: companies whose relationship with nature doesn't begin with purchasing a botanical ingredient from a supplier, but with their own agricultural resources at the very source.

For more than 20 years, OLIVE TREE PEOPLE has cultivated and protected mountain olive trees in Andalusia, Spain — not simply as inspiration for its products, but as the agricultural origin of its beauty philosophy and many of its most important ingredients.

The company doesn't simply know where its ingredients come from.

It knows the land.

It knows the trees.

It grows them.

For OLIVE TREE PEOPLE, agriculture has never been a supplier story.

IT IS WHERE BEAUTY BEGINS.

The soil.

The trees.

The leaves.

The olives.

The harvest.

The extraction.

The formulation.

The skin.

One living cycle.

FROM A DEMETER FARM AT 16 TO HIS OWN OLIVE GROVES

For founder Thomas Lommel, the moment closes a circle that began decades before OLIVE TREE PEOPLE existed.

At 16, while attending a Waldorf school in Germany, Lommel completed his first agricultural internship on a Demeter farm.

What began there as an encounter with a radically different understanding of agriculture — one in which soil, plants, animals and people are understood as parts of one living agricultural organism — would eventually become part of the philosophy behind his life's work.

Years later, that journey led him to the mountain olive trees of Andalusia.

And ultimately to OLIVE TREE PEOPLE.

"We do not take from nature and then attempt to give something back. We create a living cycle."

That distinction is fundamental.

The olive groves are not a sustainability project attached to a beauty company.

They are part of the beauty company.

OLIVE TREE PEOPLE grows and protects its own olive trees, works with their leaves and olives, extracts bioactive substances at the heart of its formulations, and develops Waterless Beauty around the olive tree rather than around water as the primary ingredient.

BEAUTY HAS TALKED ABOUT FARM-TO-FACE.

OLIVE TREE PEOPLE ACTUALLY OWNS THE FARM.

Traceability has become a major word in beauty.

Brands talk about knowing where an ingredient was grown.

OLIVE TREE PEOPLE goes considerably further.

The company is vertically connected all the way back to the living tree.

From its own agricultural resources in Andalusia to extraction, formulation and finally the skin, the company is building a beauty model in which agriculture isn't hidden somewhere at the beginning of a supply chain.

Agriculture is part of the brand itself.

And now, with its first olive groves successfully completing their Demeter audit, that agricultural foundation is moving toward one of the world's most demanding biodynamic standards.

For Lommel, this isn't a new sustainability strategy.

It is the continuation of an idea that began when he was 16.

Beauty shouldn't take something from nature and later ask how to compensate for it.

BEAUTY CAN BE A CIRCLE FROM THE BEGINNING.

So perhaps this isn't really about passing an audit.

It's about something much bigger:

One of the very few beauty companies in the world with its own agricultural resources taking those resources to an extraordinary biodynamic standard.

Rooted.

Living.

Circular.

And beginning with its own trees.

ABOUT OLIVE TREE PEOPLE

OLIVE TREE PEOPLE is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, OLIVE TREE PEOPLE develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

ABOUT OLIVEDA INTERNATIONAL, INC.

Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., together with the European companies Olive Tree People Europe AG, Oliveda Deutschland GmbH and Olive Tree Farmers SL, were founded by German real estate investor Thomas Lommel.

Lommel has more than 20 years of experience in the management and organic certification of mountain olive tree cultivation; the extraction of first-class, internationally award-winning extra virgin olive oils and hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.

Lommel is the inventor of Olive Tree Therapy 10 Years in 14 Days and of olive matcha, which is based on ground olive leaf. He also developed a unique coffee replacement based on olive leaf and hydroxytyrosol. In addition, Lommel is successfully active in the rapidly growing mindfulness industry through the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

OLIVE TREE PEOPLE's registered beauty brands include OLIVEDA, LA DOPE, OLIVE ROSE, OLIVE MUSH, IS THAT MATTY? and OLIVE re:connected to nature.

Lommel is also the region's largest conservationist and protector of more than 30,000 one-hundred-year-old mountain olive trees. Through the Thomas Lommel Foundation, he brings the water that he does not use in his waterless beauty products to the people of Africa by building water wells on site.

In addition to online sales, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand's treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine. The story is documented in the book The Olive Tree Therapy 10 Years in 14 Days.

Waterless Beauty has been called "The Next Big Thing" in articles in U.S. Vogue, Harper's Bazaar, InStyle, ELLE, Madame, Forbes and many other industry publications, as well as by Mintel, a world-leading futurology institute. Gigi Hadid and many other celebrities are already OLIVEDA fans and support its success.

Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com.

SOURCE Olive Tree People

Share this article

NEW YORK, Sept. 21, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) resulting from allegations that J.B. Hunt may have issued materially misleading business information to the investing public.

So What: If you purchased J.B. Hunt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/jb-hunt-transport-services-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 16, 2026, CNBC published an article entitled "J.B. Hunt stock plunges 10% after company warns third-quarter earnings will fall." The article further stated that J.B. Hunt's Chief Financial Officer had "said between costs for recruiting, advertising, onboarding, training and sign-on bonuses, the company expects to see about $25 million more in the third quarter compared with the second quarter."

On this news, J.B. Hunt shares fell sharply in intraday trading on September 16, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

ORLANDO, Fla., Sept. 21, 2026 /PRNewswire/ -- Xenia Hotels & Resorts, Inc. (NYSE: XHR) ("Xenia" or the "Company") today announced that its Board of Directors authorized a cash dividend of $0.14 per share of the Company's common stock for the third quarter 2026. The dividend will be paid on October 15, 2026 to all holders of record of the Company's common stock as of the close of business on September 30, 2026.

About Xenia Hotels & Resorts, Inc.

Xenia Hotels & Resorts, Inc. is a self-advised and self-administered REIT that invests in uniquely positioned luxury and upper upscale hotels and resorts with a focus on the top 25 lodging markets as well as key leisure destinations in the United States. The Company owns 29 hotels and resorts comprising 8,783 rooms across 14 states. Xenia's hotels are in the luxury and upper upscale segments, and are operated and/or licensed by industry leaders including Marriott, Hyatt, Kimpton, Fairmont, Loews, Hilton, and Davidson. For more information on Xenia's business, refer to the Company website at www.xeniareit.com.

For additional information or to receive press releases via email, please visit our website at 

www.xeniareit.com

SOURCE Xenia Hotels & Resorts, Inc.

Share this article

Drayton Valley, Alberta, selected to receive multi-year investment through the company's Thrive program

SEATTLE, Sept. 21, 2026 /PRNewswire/ -- Weyerhaeuser Company (NYSE: WY) today announced a commitment to invest $1 million in Drayton Valley, Alberta, through the company's Thrive program. The investment will be made over the next several years with input from local elected officials, business leaders, nonprofits, employees and other community partners. Drayton Valley is the first community in Canada to be selected for the program, reflecting the company's long-term commitment to its Canadian operations.

"We have a responsibility to our rural operating communities to help them remain great places to live, work and do business for generations to come, and we launched our Thrive program several years ago to amplify the positive impact and support we can provide locally," says Devin W. Stockfish, president and chief executive officer. "We're looking forward to working with community leaders in Drayton Valley to address priority needs and provide meaningful long-term benefits."

Drayton Valley is a community of approximately 8,000 people located about 90 minutes southwest of Edmonton. Weyerhaeuser, which operates six manufacturing facilities across Canada, has operated a sawmill in Drayton Valley for nearly 40 years and in 2013 announced a $23 million investment in production upgrades. Today, the company employs approximately 450 people through its sawmill and surrounding forestry operations, making Weyerhaeuser the largest employer in the region.

"Weyerhaeuser is an important part of our community and a respected industry leader whose longstanding presence, investment and support continue to make a meaningful difference in Drayton Valley and the surrounding area," says Nancy Dodds, mayor of Drayton Valley. "We are deeply grateful for the strong partnership and trusted relationship we have built over the years, and we are thrilled to have been selected for this opportunity through the Thrive program. We look forward to working alongside Weyerhaeuser leaders and community members to identify our highest priorities and ensure this investment has a lasting impact as we build a stronger, healthier and more resilient future together."

Weyerhaeuser's Thrive program is a key pillar of the company's broader 3 by 30 Sustainability Ambition around rural communities and goes far beyond the financial investment. In selected communities, Weyerhaeuser leaders engage deeply with local stakeholders to identify and prioritize the challenges to be addressed through long-term collaboration, investment and advocacy. Potential opportunities in Drayton Valley will be explored by Weyerhaeuser and community leaders in the weeks and months ahead.

"We're here to listen to the needs of the community and work with local stakeholders, including our employees, to understand where we can make the biggest impact together," says Nancy Thompson, senior director of Advocacy and Philanthropy. "We'll be reaching out to community organizations and partners in the coming weeks to understand where our investment can make the biggest difference."

Each of Weyerhaeuser's three previously announced Thrive communities — Zwolle, Louisiana (2023), Raymond, Washington (2024), and Buckhannon, West Virginia (2025) — identified different priorities for investment. In Zwolle, improvements to local ballfields have been completed, and significant progress has been made in upgrading the city's water infrastructure. In Raymond, a workforce housing initiative launched earlier this year, and in Buckhannon, early discussions have focused on educational opportunities with a potential to improve STEAM education.

Weyerhaeuser launched Thrive in 2023 to provide additional resources and support to five of its rural operating communities across North America. Weyerhaeuser plans to announce its fifth Thrive community, completing the company's initial program commitment, later this year. Selected communities represent areas where Weyerhaeuser has a significant presence and a history of employee and leadership engagement; where there are opportunities to take advantage of external resources, such as federal or state/provincial infrastructure grants, to strengthen advocacy efforts; and where Weyerhaeuser can partner with other employers, nonprofits and community leaders to amplify efforts and impact on the ground.

ABOUT WEYERHAEUSER

Weyerhaeuser Company, one of the world's largest private owners of timberlands, began operations in 1900 and today owns or controls more than 10 million acres of timberlands in the U.S., as well as additional public timberlands managed under long-term licenses in Canada. Weyerhaeuser has been a global leader in sustainability for more than a century and manages 100 percent of its timberlands on a fully sustainable basis in compliance with internationally recognized sustainable forestry standards. Weyerhaeuser is also one of the largest manufacturers of wood products in North America and operates additional business lines around product distribution, climate solutions, real estate, energy and natural resources, among others. In 2025, the company generated $6.9 billion in net sales and employed approximately 9,500 people who serve customers worldwide. Operated as a real estate investment trust, Weyerhaeuser's common stock trades on the New York Stock Exchange under the symbol WY. Learn more at www.weyerhaeuser.com.

For more information contact:

Analysts – Andy Taylor, 206-539-3907

Media – Nancy Thompson, 919-861-0342

SOURCE Weyerhaeuser Company

Share this article